Publication:
The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis

dc.contributor.coauthorSiriopol, Dimitrie
dc.contributor.coauthorPopa, Raluca
dc.contributor.coauthorOrtiz, Alberto
dc.contributor.coauthorPerazella, Mark A.
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.kuauthorYıldız, Abdullah Burak
dc.contributor.kuauthorBerkkan, Metehan
dc.contributor.kuauthorHasbal, Nuri Barış
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileResearcher
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.contributor.yokid110580
dc.contributor.yokid368625
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T13:48:47Z
dc.description.abstractLay summary: immune checkpoint inhibitors are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality. Background: immune checkpoint inhibitors (ICPIs) are a novel therapeutic approach to cancer treatment that have changed the landscape of cancer therapy but also have some considerable drawbacks. Acute kidney injury (AKI) is one of these potential complications that may have effects on patient outcomes. In this review, we assessed the effect of AKI on mortality outcomes in cancer patients receiving this immunotherapy. Methods: we performed a systematic review and meta-analysis of prospective, retrospective, randomized and non-randomized studies, which examined the effects of AKI in cancer patients receiving immune checkpoint inhibitors. We searched through PubMed, Medline, Web of Science, Scopus, and Cochrane Library databases. Results: seven studies were included in the final analysis, with a total number of patients of 761. Overall, the risk of death was higher in patients that developed AKI during ICPI treatment [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05-1.92, P = 0.02; heterogeneity chi(2) = 11.68, I-2 = 66%, P = 0.02] compared with patients that did not develop AKI. In addition, there was a trend to a better survival in those with less severe AKI patients compared with those with more severe AKI (HR 1.35, 95% CI 0.99-1.83, P = 0.05). Lastly, it was seen that patients with persistent kidney dysfunction (non-recovery) had an increased risk for all-cause mortality (HR 2.93, 95% CI 1.41-6.08, P = 0.004; heterogeneity chi(2) = 0.53, I-2 = 0%, P = 0.47). Conclusions: development of AKI in patients with cancer receiving immune checkpoint inhibitors is associated with increased risk of mortality.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.issue5
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume16
dc.formatpdf
dc.identifier.doi10.1093/ckj/sfac194
dc.identifier.eissn2048-8513
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03993
dc.identifier.issn2048-8505
dc.identifier.linkhttps://doi.org/10.1093/ckj/sfac194
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85140651196
dc.identifier.urihttps://hdl.handle.net/20.500.14288/3837
dc.identifier.wos853461900001
dc.keywordsAcute kidney injury
dc.keywordsAcute renal failure
dc.keywordsImmune checkpoint inhibitors
dc.keywordsImmunotherapy
dc.keywordsNephrotoxicity
dc.languageEnglish
dc.publisherOxford University Press (OUP)
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10872
dc.sourceClinical Kidney Journal
dc.subjectUrology and nephrology
dc.titleThe association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
dc.typeReview
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.authorid0000-0003-0190-2746
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorYıldız, Abdullah Burak
local.contributor.kuauthorBerkkan, Metehan
local.contributor.kuauthorHasbal, Nuri Barış

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10872.pdf
Size:
824.51 KB
Format:
Adobe Portable Document Format